M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID

Abstract Background Opioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID). HIV pre-exposure prophylaxis (PrEP) and HCV treatment regimens have transformative potential to...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Valérie Martel-Laferrière, Daniel J. Feaster, Lisa R. Metsch, Bruce R. Shackman, Christine Loignon, Bohdan Nosyk, Hansel Tookes, Czarina N. Behrends, Nelson Arruda, Oluleye Adigun, Marie-Eve Goyer, Michael A. Kolber, Jean-Francois Mary, Allan E. Rodriguez, Iveth G. Yanez, Yue Pan, Rania Khemiri, Lauren Gooden, Aïssata Sako, Julie Bruneau
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2022-04-01
Серии:Trials
Предметы:
Pre-exposure prophylaxis (PrEP)
Hepatitis C treatment
People who inject drugs
Patient navigator
Adherence counselor
Online-ссылка:https://doi.org/10.1186/s13063-022-06085-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы